SCHEMBL19137962

SCHEMBL19137962

CN1CCN(c2ccc(-c3nc4cc(C(F)(F)F)c(Cl)cc4[nH]3)cc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 2/20 0.67
▸ SOAT1 P35610 2/20 0.67
▸ KCNH2 Q12809 2/20 0.67
▸ SMN1; SMN2 Q16637 5/20 0.54
▸ ALDH1A1 P00352 4/20 0.54
▸ TOP1 P11387 3/20 0.54
▸ TOP2A P11388 3/20 0.54
▸ HPGD P15428 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ MAPT P10636 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ BLM P54132 2/20 0.50
▸ TNKS O95271 1/20 0.50
▸ PARP1 P09874 1/20 0.50
▸ TNKS2 Q9H2K2 1/20 0.50
▸ SLCO2B1 O94956 1/20 0.50
▸ GLA P06280 1/20 0.50
▸ RECQL P46063 1/20 0.50
▸ BCL2L1 Q07817 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19137958 0.90 DGAT1 (0.53) DGAT1SOAT1KCNH2SMN1; SMN2MAPT
SCHEMBL19137928 0.89 DGAT1 (0.52) DGAT1SOAT1KCNH2SMN1; SMN2MAPT
SCHEMBL19137940 0.88 DGAT1 (0.68) DGAT1SOAT1KCNH2SMN1; SMN2ALDH1A1
SCHEMBL19137965 0.87 DGAT1 (0.63) DGAT1SOAT1KCNH2SMN1; SMN2ALDH1A1
SCHEMBL19137939 0.85 DGAT1 (0.61) DGAT1SOAT1KCNH2SMN1; SMN2ALDH1A1
SCHEMBL19175932 0.84 DGAT1 (0.59) DGAT1SOAT1KCNH2SMN1; SMN2ALDH1A1
SCHEMBL19137948 0.81 DGAT1 (0.98) DGAT1SOAT1KCNH2SMN1; SMN2ALDH1A1
SCHEMBL19175762 0.80 KCNH2 (0.58) DGAT1SOAT1KCNH2SMN1; SMN2ALDH1A1
SCHEMBL24075398 0.80 DGAT1 (0.66) DGAT1SOAT1KCNH2SMN1; SMN2ALDH1A1
SCHEMBL21017604 0.79 DGAT1 (0.63) DGAT1SOAT1KCNH2SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170210741-A1 Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof SOUTHERN RESEARCH INSTITUTE 2017-07-27 — — US disclosed
US-20170210741-A1 Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof SOUTHERN RESEARCH INSTITUTE 2017-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170210741-A1 Benzimidazole Compounds, Use As Inhibitors of WNT Signaling Pathway in Cancers, and Methods for Preparation Thereof WNT1, WNT3, CTNNB1 DGAT1 2252/4885SOAT1 2222/4885KCNH2 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback